Document Detail

Nitric oxide for the treatment of preterm infants with respiratory distress syndrome.
MedLine Citation:
PMID:  23194109     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Inhaled Nitric oxide (iNO) has been proposed as effective treatment for improving oxygenation in preterm infants with respiratory distress syndrome (RDS), and for preventing the development of bronchopulmonary dysplasia (BPD).
AREAS COVERED: This drug evaluation mainly reviews the results of clinical studies on the effects of iNO in preterm infants with RDS which have provided contradictory results probably due to their different designs. Three recent meta-analyses of these studies have concluded that iNO therapy is not effective in decreasing the risk of death and BPD and cannot be recommended as routine treatment. The same meta-analyses suggest that some strategy of iNO treatment and some subgroups of patients, such as infants with persistent pulmonary hypertension of the newborn (PPHN), should be further studied.
EXPERT OPINION: At present, the available evidence does not support the use of iNO in preterm infants with RDS, and iNO therapy cannot be recommended for the routine treatment of respiratory failure in premature neonates. In the future, further studies in selected populations using adequate doses and investigating the effectiveness of other drugs, such as sildenafil, might affect the use and diffusion of iNO.
Carlo Dani; Simone Pratesi
Related Documents :
18300929 - Effects of a neurodevelopmental treatment-based trunk protocol for infants with posture...
6354629 - Developmental lags in preterm infants from one to three years of age.
19447409 - Paco2 and neurodevelopment in extremely low birth weight infants.
9213229 - Primitive reflexes and early motor development.
24397409 - Correlation analysis between echocardiographic flow pattern and n-terminal-pro-brain na...
23448699 - Doxapram and hypokalaemia in very preterm infants.
10850499 - Antioxidant capacity and oxygen radical diseases in the preterm newborn.
8438919 - Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfac...
19437209 - Event-related potentials to point-light displays of human actions in five-month-old inf...
Publication Detail:
Type:  Journal Article; Review     Date:  2012-11-30
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  14     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2012-12-25     Completed Date:  2013-06-20     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  97-103     Citation Subset:  IM    
Careggi University Hospital of Florence, Department of Surgical and Medical Critical Care, Section of Neonatology, Viale Morgagni, 85, 50134 Florence, Italy. cdani@unifi.It
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Bronchodilator Agents / administration & dosage,  therapeutic use*
Bronchopulmonary Dysplasia / etiology,  prevention & control*
Infant, Newborn
Meta-Analysis as Topic
Nitric Oxide / administration & dosage,  therapeutic use*
Persistent Fetal Circulation Syndrome / drug therapy
Randomized Controlled Trials as Topic
Respiratory Distress Syndrome, Newborn / complications,  drug therapy*,  mortality
Survival Rate
Reg. No./Substance:
0/Bronchodilator Agents; 10102-43-9/Nitric Oxide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Characterization of Dicrocoelium chinensis from domestic yaks in Gansu and Sichuan provinces, China,...
Next Document:  Expression of cell proliferation cycle negative regulators in fibroblasts of an ischemic diabetic fo...